Compass Pathways Email Format
Mental Health CareEngland, United Kingdom201-500 Employees
Compass Pathways is a mid-sized biotechnology company based in London, England, focused on accelerating patient access to evidence-based innovations in mental health care. Its lead program centers on COMP360, a synthetic psilocybin treatment being studied for treatment-resistant depression. The company aims to transform the patient experience by advancing novel therapies from research into clinical practice within mental health care. In April 2026, Compass Pathways announced a partnership with King’s College London to run trials and coordinate a UK manufacturing plan for export to the United States ahead of regulatory approval.